ENTPD6 Antibody

What is ENTPD6 and why is it studied in research?

ENTPD6 (ectonucleoside triphosphate diphosphohydrolase 6) is a protein that supports glycosylation reactions in the Golgi apparatus and catalyzes the hydrolysis of extracellular nucleotides when released from cells. It preferentially hydrolyzes nucleoside 5'-diphosphates, while nucleoside 5'-triphosphates are hydrolyzed only to a minor extent. There is no hydrolysis of nucleoside 5'-monophosphates. The order of activity with different substrates is GDP > IDP >> UDP = CDP >> ADP. ENTPD6 is studied to understand cellular processes related to nucleotide metabolism and potential roles in various physiological and pathological conditions .

What applications are ENTPD6 antibodies typically used for?

ENTPD6 antibodies are commonly used in Western Blotting (WB), Immunohistochemistry (IHC), and ELISA applications. These techniques allow researchers to detect and quantify ENTPD6 protein in various biological samples. For optimal results, antibodies should be titrated for each specific application and sample type . Some antibodies may also be suitable for immunoprecipitation (IP) depending on the specific product .

What sample types can be used with ENTPD6 antibodies?

ENTPD6 antibodies have demonstrated reactivity with human, mouse, and rat samples. Specific antibodies have been validated for detection in tissues such as mouse spleen tissue for Western blotting and human prostate cancer tissue for immunohistochemistry. For ELISA applications, these antibodies can be used with undiluted original human body fluids, tissue homogenates, secretions, or feces samples .

What is the recommended storage condition for ENTPD6 antibodies?

ENTPD6 antibodies should typically be stored at -20°C. Most products remain stable for one year after shipment when properly stored. For many formulations, aliquoting is unnecessary for -20°C storage. The antibodies are commonly supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. It's important to note that sodium azide is a poisonous and hazardous substance that should be handled by trained staff only .

How should I determine the optimal antibody dilution for my experiment?

The optimal antibody dilution varies depending on the application and specific sample characteristics. For Western Blot applications, recommended dilutions typically range from 1:500 to 1:2000. For Immunohistochemistry, recommended dilutions range from 1:20 to 1:200. It is strongly recommended to titrate the antibody in each testing system to obtain optimal results, as the optimal dilution can be sample-dependent. Start with the manufacturer's recommended range and perform a dilution series to determine the concentration that provides the best signal-to-noise ratio for your specific sample and experimental conditions .

What antigen retrieval methods are recommended for IHC with ENTPD6 antibodies?

For immunohistochemistry applications using ENTPD6 antibodies, it is suggested to perform antigen retrieval with TE buffer at pH 9.0. Alternatively, antigen retrieval may be performed with citrate buffer at pH 6.0. The choice between these methods may depend on the specific tissue type and fixation method used. It's advisable to compare both methods with your specific samples to determine which provides optimal staining with minimal background .

How can I validate the specificity of ENTPD6 antibody detection?

To validate antibody specificity, consider implementing the following approaches:

• Compare staining patterns with multiple antibodies targeting different epitopes of ENTPD6

• Include positive controls (tissues known to express ENTPD6, such as mouse spleen)

• Include negative controls (tissues with low/no ENTPD6 expression)

• Perform blocking experiments with the immunizing peptide

• Correlate protein detection with mRNA expression data

• Consider siRNA knockdown or CRISPR knockout in cell lines to confirm specificity

The expected molecular weight for ENTPD6 is approximately 60 kDa in Western blot applications, which can serve as an additional validation criterion .

Why might I observe differences between calculated and observed molecular weights for ENTPD6?

The calculated molecular weight of ENTPD6 is 53 kDa (483 amino acids), but the observed molecular weight in Western blot applications is typically around 60 kDa. This discrepancy is likely due to post-translational modifications, particularly glycosylation, which is consistent with ENTPD6's function in supporting glycosylation reactions in the Golgi apparatus. When troubleshooting Western blots, be aware that glycosylated proteins often migrate more slowly in SDS-PAGE than their calculated molecular weight would predict .

What are common issues in ENTPD6 immunodetection and how can they be resolved?

Common issues include:

• High background: Increase blocking time/concentration, optimize antibody dilution, or try different blocking agents

• Weak or no signal: Ensure proper antigen retrieval, increase antibody concentration, extend incubation time, or verify sample expression levels

• Non-specific bands: Increase antibody dilution, optimize washing steps, or verify antibody specificity

• Inconsistent results: Standardize protocols, use fresh reagents, and ensure consistent sample preparation

If experiencing issues with IHC, it may be helpful to compare results using both suggested antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0) to determine which works best with your specific tissue samples .

How can ENTPD6 antibodies be used to investigate its role in nucleotide metabolism?

To investigate ENTPD6's role in nucleotide metabolism, researchers can:

• Use immunofluorescence with subcellular markers to confirm Golgi localization

• Perform co-immunoprecipitation experiments to identify protein interaction partners

• Compare ENTPD6 expression levels across tissues with different nucleotide metabolism profiles

• Correlate ENTPD6 expression with enzymatic activity assays for nucleoside diphosphate hydrolysis

• Combine ENTPD6 immunostaining with functional assays measuring substrate (GDP, IDP, UDP, CDP, ADP) hydrolysis

These approaches can help elucidate the functional significance of ENTPD6 in cellular nucleotide homeostasis and metabolism .

What considerations are important when using ENTPD6 antibodies in multiplex immunoassays?

When designing multiplex immunoassays including ENTPD6 antibodies:

• Host species compatibility: Select primary antibodies from different host species to avoid cross-reactivity with secondary antibodies

• Spectral overlap: Choose fluorophores with minimal spectral overlap when using fluorescent detection

• Epitope accessibility: Consider whether multiple antibodies might compete for adjacent epitopes

• Optimal dilutions: Re-optimize dilutions for each antibody in the multiplex context

• Sequential staining: Consider sequential rather than simultaneous staining if steric hindrance is observed

• Validation: Validate multiplex results against single-plex controls to ensure specificity is maintained

These considerations help ensure reliable and specific detection of multiple targets including ENTPD6 in the same sample .

How can ENTPD6 expression be accurately quantified across different sample types?

For accurate quantification of ENTPD6 across different sample types:

• Western blot quantification: Use housekeeping proteins as loading controls and densitometry software for relative quantification

• ELISA-based quantification: Develop standard curves using recombinant ENTPD6 protein

• IHC quantification: Employ digital image analysis with appropriate positive and negative controls

• Normalization strategies: Normalize to total protein, tissue area, or cell number depending on the sample type

• Cross-platform validation: Verify results using multiple detection methods (e.g., WB and ELISA)

For ELISA applications specifically, the ENTPD6 ELISA kit is designed to detect native, not recombinant, ENTPD6 in undiluted body fluids, tissue homogenates, secretions, or feces samples .

How can ENTPD6 antibodies be optimized for detecting expression changes in cancer tissues?

For optimal detection of ENTPD6 expression changes in cancer tissues:

• Sample preparation: Ensure consistent fixation and processing protocols

• Antigen retrieval optimization: Compare TE buffer (pH 9.0) and citrate buffer (pH 6.0) to determine optimal conditions for cancer tissue specimens

• Antibody titration: Re-optimize antibody dilutions specifically for cancer tissues, which may have altered protein expression levels

• Controls: Include matched normal tissues as controls

• Quantification: Implement digital pathology approaches for objective quantification

• Multiplex analysis: Consider combining with cancer markers to correlate ENTPD6 expression with cancer phenotypes

ENTPD6 antibodies have been successfully used for IHC in human prostate cancer tissue, suggesting potential applications in cancer research .

What approaches can be used to correlate ENTPD6 protein levels with enzymatic activity?

To correlate ENTPD6 protein levels with enzymatic activity:

• Parallel assays: Perform Western blot or ELISA to quantify ENTPD6 protein levels in parallel with nucleotidase activity assays

• Activity assays: Measure the hydrolysis rates of preferred substrates (GDP > IDP >> UDP = CDP >> ADP)

• Inhibition studies: Use specific inhibitors or blocking antibodies to confirm the contribution of ENTPD6 to observed nucleotidase activity

• Overexpression/knockdown: Correlate changes in protein levels (via Western blot) with changes in enzymatic activity following genetic manipulation

• In situ approaches: Combine immunohistochemistry with histochemical enzyme activity assays on sequential tissue sections

This multi-faceted approach helps establish whether ENTPD6 protein levels directly correlate with functional enzymatic activity in biological samples .

How should I normalize and compare ENTPD6 expression data across multiple experiments?

For robust normalization and comparison of ENTPD6 expression data:

• Western blot normalization:

  • Use consistent loading controls (e.g., GAPDH, beta-actin)

  • Apply total protein normalization methods (e.g., stain-free technology)

  • Include inter-gel calibrators when comparing across multiple blots

• IHC normalization:

  • Use standardized staining protocols and image acquisition settings

  • Include control tissues on each slide

  • Apply digital image analysis with consistent thresholding methods

• Statistical approaches:

  • Calculate coefficients of variation to assess reproducibility

  • Apply appropriate statistical tests based on data distribution

  • Consider using mixed-effects models for experiments with multiple variables

• Metadata documentation:

  • Record all experimental conditions, antibody lots, and protocol variations

  • Use this information to account for batch effects in analysis

These approaches help ensure that observed differences in ENTPD6 expression are biologically meaningful rather than technical artifacts .

What are appropriate positive and negative controls for ENTPD6 antibody validation?

For comprehensive ENTPD6 antibody validation:

Positive Controls:

• Mouse spleen tissue (validated for Western blot)

• Human prostate cancer tissue (validated for IHC)

• Cell lines with known ENTPD6 expression (e.g., Golgi-rich cell types)

Negative Controls:

• Tissues with minimal ENTPD6 expression (based on transcriptomic data)

• Samples processed without primary antibody

• Antibody pre-adsorbed with immunizing peptide

• siRNA knockdown or CRISPR knockout cell lines

Methodological Controls:

• Comparing multiple antibodies targeting different ENTPD6 epitopes

• Testing multiple dilutions to establish specificity

• Comparing different detection methods (e.g., fluorescent vs. chromogenic)

Proper controls are essential for confirming staining specificity and optimizing protocols for different applications .